Hi Glitterati - good find. I am also reading about mental health ramifications of the continued stressors resulting from Covid on the general population. Stress is also a problem for the immune system.....and we know that CBD is very effective here, just as an aside.
The GAD (General Anxiety Disorder) Psylocybin program just fits hand in glove with this lift in the number of chronic anxiety sufferers. This is a study unique to IHL. The beauty here is that I think there is no doubt from an industry perspective that Psylocybin is effective - so the risk at the clinical trial level is mitigated tremendously.
Also looking forward to IHL announcing details of the second psychedelics trial........
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-6487
-
- There are more pages in this discussion • 13,961 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)